Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

78.90 +0.42 (+0.54%)
Delayed Quote Updated: 3:40 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Tempus AI Surges on Earnings Beat, But Can the Rally Last? ↗
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside. 
Via MarketBeat
Topics Artificial Intelligence Earnings Initial Public Offering
News headline image
Tempus (TEM) Q3 2026 Earnings Call Transcript ↗
Oncology volume surged 32% while data licensing bookings topped $550 million year-to-date. 
Via The Motley Fool
Topics Earnings
News headline image
Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction ↗
Tempus AI raised its outlook on 23% revenue growth, but most of its smaller net loss came from paper gains on stock it holds, not the core business. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
What Tempus AI (TEM) Said on Its Q3 Earnings Call ↗
Tempus AI (NASDAQ:TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Tempus Reports Third Quarter 2026 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
From Tempus AI, Inc.
Via Business Wire
News headline image
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
From Pathos AI
Via Business Wire
News headline image
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
From Tempus AI, Inc.
Via Business Wire
News headline image
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Tempus to Report Third Quarter 2026 Financial Results on November 2
From Tempus AI, Inc.
Via Business Wire
News headline image
The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape
AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034 New York, NY – October 15,... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape
AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034 
From FN Media
Via GlobeNewswire
News headline image
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
From Ambry Genetics
Via Business Wire
News headline image
Tempus Announces Multi-Year Collaboration with Moderna and Merck
From Tempus
Via Business Wire
News headline image
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus AI Chief Accounting Officer Sells $529,650 of Stock ↗
Sale follows 30% rebound in the stock year to date. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion ↗
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
From Tempus AI, Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Tempus AI Director Nadja West Sells 3,000 Shares for $207,000 ↗
Sale executed under pre-established Rule 10b5-1 trading plan adopted in May, leaving West with 31,981 shares and a 0.0183% ownership stake. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Cathie Wood Invested Roughly $1.4 Billion of Ark Invest's Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks ↗
Wood is known for being a tech-first investor. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Earnings
News headline image
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
From Tempus AI, Inc.
Via Business Wire
News headline image
Why Tempus AI Skyrocketed This Week ↗
Tempus AI's latest acquisition is looking like a great move. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know ↗
West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.